Influence of oestrogen administration in vivo and in vitro on the release and synthesis of prolactin from incubated pituitaries

The release and synthesis of prolactin were studied in incubated adenohypophyses from ovariectomized rats. After a 4 h incubation period the prolactin concentration in the medium markedly increased whereas that in the gland was reduced. However, the concentration of prolactin in the system, tissue plus medium, after 4 h was almost twice as much as that present at the beginning of incubation indicating spontaneous synthesis. This spontaneous release and synthesis of prolactin was greatly increased in incubated glands from ovariectomized oestrogen-treated rats. Oestradiol benzoate was injected in doses of 2.5, 5.0 or 10.0 microgram/rat 2 or 24 h before killing the animals. Lower effects were obtained in glands from 2 h-oestradiol-pre-treated rats than from 24 h-oestradiol-primed rats. Oestradiol-17beta (55, 166, 500 and 1500 ng/ml) added to the incubation medium also enhanced the release and synthesis of prolactin and the effect was more marked in glands from oestrogen injected rats than in those of non-treated animals. The increase was dose-related although the higher doses were less effective. These results provide further evidence of the effect of oestrogen on the release and synthesis of prolactin by a direct action on the pituitary gland. They also show that oestradiol pre-treatment in vivo increase the response of the prolactin cells towards oestradiol in vitro.     

Interaction of thyrotrophin releasing hormone with inhibin in male rats

Inhibin administered to adult male rats delayed the in-vivo pituitary responsiveness to thyrotrophin releasing hormone (TRH) as observed in terms of prolactin release in the serum. It also decreased the sensitivity of the pituitary gland to TRH, in terms of TSH release. However, inhibin alone did not alter the serum levels of prolactin and TSH, although it significantly suppressed serum FSH levels. In addition, the inhibin effect on FSH release was blocked by TRH.     

Serum thyrotrophin, prolactin and growth hormone, response to TRH during oestrogen treatment.

The serum levels of thyrotrophin (TSH), prolactin (PRL) and growth hormone (GH) and the response of these hormones to 500 mug thyrotrophin-releasing hormone (TRH) iv were studied in menstruating women, in post-menopausal women before and after 2 mg oestradiol valerate for 5 consecutive days, and in men on long term oestrogen treatment. Oestrogen treatment had no effect on basal serum TSH levels, which were within the normal range in all groups. The TSH response to TRH was not different in menstruating and post-menopausal women and was not changed in the latter group after oestrogen treatment. In men treated chronically with oestrogens, the TSH response to TRH was similar to that found in normal male subjects.     

Effects of infusion of thyrotrophin releasing hormone and dopamine either alone or in combination on plasma prolactin concentrations in the anoestrous ewe

Plasma concentrations of prolactin in anoestrous ewes were respectively lowered or raised by the separate infusion of dopamine or thyrotrophin releasing hormone (TRH). Combined treatment with dopamine and TRH lowered the concentration of prolactin in plasma but the values increased markedly after the treatment was stopped and reached a level equivalent to that found in ewes treated with TRH alone. The results are interpreted as evidence that both dopamine and TRH play a regulatory role in determining the secretion of prolactin in the ewe.     

Light and electron microscopic studies of thyrotrophin releasing hormone-induced growth hormone and prolactin release in hypophysectomized rats bearing an ectopic pituitary gland.

A light microscopic and ultrastructural study of anterior pituitary glands transplanted under the kidney capsule of hypophysectomized rats was performed, in basal conditions and after stimulation with thyrotrophin releasing hormone, at various intervals (24 h-2 months) after transplantation. Confirming previous biochemical findings, the results suggest that with time, somatotrophs acquire sensitivity to thyrotrophin releasing hormone and respond with increased exocytosis at doses that were found ineffective in pituitary glands in situ. Thyrotrophin releasing hormone stimulation did not seem to influence the morphology of prolactin cells, which were already highly active under basal conditions at all time intervals.     

The thyrotrophin response to thyrotrophin releasing hormone during treatment in patients with Graves' disease.

Thyrotrophin releasing hormone (TRH) tests were performed at 4 or 8 weeks intervals, after the initiation of anti-thyroid treatment in 15 patients with Graves' disease. All TRH test were negative as long as the serum levels of thyroxine (T4) and triiodothyronine (T3) were elevated, and normalization of the serum levels of these hormones always occurred before the response to iv TRH was restored. In 13 patients the time from the patients for the first time were registered as biochemically euthyroid varied from 0-9 months (mean 3.1 months), before TRH response was restored. Two patients were still TRH non-responsive at the end of the study, even though they had been biochemically euthyroid for as long as 17 and 18.5 months. The TRH test, therefore, is not helpful in the evaluation of the effect of anti-thyroid treatment in patients with Graves' disease. There was an increase in the serum level of (TSH) from 3.4 +/- 0.3 (SEM) to 4.3 +/- 0.5 (SEM) ng/ml (P less than 0.05), and a decrease in the serum level of total T4 from 19.4 +/- 1.1 (SEM) to 5.8 +/- 0.8 (SEM) microng/100 ml in 13 patients from the first examination until the last time they were examined before restored TRH response. This finding shows that the pituitary gland has retained its ability to synthesize and secrete TSH even though no TSH could be released by iv TRH. In 6 TRH non-responsive patients with Graves' disease, serum TSH levels were suppressed from 2.5 +/- 1.2 (SEM) ng/ml before the administration of a single dose of 3 mg T4 orally, to 0.9 +/- 0.2 (SEM) ng/ml, 7 days after the T4 administration. Thus, the negative feed-back effect on the pituitary gland of the thyroid hormones is operating in these patients. This finding indicates that the TRH non-responsiveness in euthyroid patients with Graves' disease is not due to pituitary depletion of TSH, since the negative feed-back effect of the thyroid hormones is operating normally.     

In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.

To determine the site of action of dopaminergic drugs on human PRL and GH release from pituitary adenomas, five PRL-and five GH-secreting adenomas were incubated with and without dopamine and L-dopa. Bromocriptine was also tested in order to compare its effect to that of the other drugs. In all of the experiments except one, a decrease of PRL, which was often statistically significant, was observed. When pooling the results of the PRL-secreting adenomas, the mean levels of PRL with dopamine, L-dopa, and bromocriptine were, respectively, 49%, 55%, and 60% of the control levels. In the GH-secreting adenomas, they were 60%, 67%, and 55% of that of the control. For GH, a decrease of the release was observed in four out of five GH-secreting adenomas. When pooling the results from these tumors, the mean levels of GH with dopamine, L-dopa, and bromocriptine were, respectively, 63%, 76%, and 64% of the control levels. In one case, a significant increase of GH was observed with the three dopaminergic drugs. This study produced the following conclusions. 1) Dopamine acts directly on PRL and GH release from human pituitary adenomas; in vitro, L-dopa effects are similar (its action probably occurs after conversion to catecholamines). These observations strongly suggest the presence of dopaminergic membrane receptors on human lactotroph and somatotroph adenomatous pituitary cells. 2) In vitro hormonal results are in good agreement with in vivo dynamic tests using L-dopa and bromocriptine. 3) The paradoxical effect of dopaminergic drugs on GH secretion in acromegalic patients may be attributed to modified dopamine membrane receptors. However, the paradoxical response is not a constant feature in acromegaly, and its mechanism needs further investigations.     

A priming effect of luteinizing hormone releasing factor with respect to release of follicle-stimulating hormone in vitro and in vivo.

Pituitary incubation studies were carried out which showed that in the rat luteinizing hormone releasing factor (LH-RF) can exert a priming effect on FSH secretion in vitro. It was found that, as for LH, the effect depends on protein synthesis. The priming effect of LH-RF with respect to FSH could also be demonstrated in vivo; however, the effect was less dramatic than for LH.     

Influence of dopamine on the altered release of prolactin, luteinizing hormone, and follicle-stimulating hormone induced by interleukin-2 in vitro.

Interleukin-2 (IL-2) alters the release of anterior pituitary hormones at femtomolar concentrations from hemipituitaries incubated in vitro. This cytokine significantly lowered luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and stimulated prolactin (PRL) release, thus demonstrating a reciprocal action of the lymphokine on lactotrophs and gonadotrophs. Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Hemipituitaries were incubated with varying concentrations of DA, a combination of IL-2 plus DA, or a combination of haloperidol (1 x 10(-5) M) with DA for 1 h, followed subsequently by incubation with medium containing only high potassium (K+) to study the effects on depolarization-induced hormone release. DA induced a dose-related, significant lowering of the basal PRL release with a minimal effective dose (MED) of less than 19 nM. The depolarization-induced PRL release was also inhibited, but the MED was 100-fold higher than the MED to inhibit basal PRL release. DA at much higher concentrations (30, 60, and 90 microM) significantly reduced pituitary PRL content. The addition of 0.187, 3.75, 15, or 60 microM DA to IL-2-induced PRL release. IL-2 (10(-15) M) produced a significant decrease in LH and FSH release. The combination of 3.75 or 15 microM DA plus IL-2 failed to alter the IL-2 suppressed LH release, whereas the addition of 0.187 microM DA to IL-2 blocked its suppressive influence, and 60 microM DA added to Il-2 produced an additive inhibitory effect. Thus, the interaction of IL-2 and DA is biphasic on LH release. The significant reduction of FSH release induced by IL-2 was blocked in the presence of 0.187, 3.75, 15, or 60 microM DA. DA alone at relatively high concentrations of 30, 60, and 90 microM suppressed basal LH and FSH release. The effects of DA on PRL, LH, and FSH at all doses tested were blocked by the DA receptor blocker, haloperidol which by itself at the concentration tested (1 x 10(-5) M) had no effect. Thus, the actions of DA at all concentrations tested appear to be mediated via DA receptors. In conclusion, DA was capable of blocking the stimulatory action of IL-2 on PRL release and its inhibitory action on FSH release by a DA receptor mediated action.(ABSTRACT TRUNCATED AT 400 WORDS)     

Growth hormone and prolactin release in acromegalic patients following metergoline administration.

In six acromegalite patients oral administration of 4 mg of metergoline, an antiserotonin agent, produced a fall in plasma growth hormone (GH) and prolactin (PRL) concentrations. In the same patients this inhibitory effect was observed after administration of dopaminergic drugs, L-Dopa and 2-Br-alpha-ergocryptine. Both GH and PRL levels remained suppressed during a 6 day course of treatmnt with metergoline. These results are consistent with the hypothesis that the inhibitory effect of netergoline on GH and PRL release is determined by inactivation of serotonin receptors in the hypothalamus or at the pituitary.     

The influence of amino acids and somatostatin on prolactin and growth hormone release in man.

The effect of an iv load of individual amino acids (alanine, arginine, histidine, leucine, phenylalanine, and valine) on serum prolactin (Prl) and growth hormone (GH) concentrations was studied in healthy adult males (n = 5). A rise in both, Prl and GH with a maximal increment of 15.9 +/- 6.7 (SE) ng/ml, and 12.4 +/- 4.9 ng/ml above basal levels, respectively, (P less than 0.05) was observed after iv arginine. Following iv phenylalanine the mean peak level of Prl rose from 9.9 +/- 3.5 to 29.9 +/- 7.3 ng/ml (P less than 0.01), whereas GH concentration remained unchanged. Iv leucine however induced an immediate rise in GH, but not in serum Prl. Serum concentrations of both, Prl and GH, failed to increase upon the infusion of either alanine or histidine or valine. Additional somatostatin administration starting prior to amino acid infusion diminished the amino acid induced increase of both Prl and GH release.     

Effect of morphine on the release of thyroid-stimulating hormone stimulated by exposure to cold, thyroidectomy and the administration of thyrotrophin releasing hormone in male rats

Morphine reduced the release of thyroid-stimulating hormone (TSH) which stimulated by exposure to cold and by thyroidectomy as well as reducing the basal level of TSH in the serum of male rats. Thi inhibitory effect of morphine was antagonized by naloxone which did not enhance the basal or cold-induced TSH release. Pretreatment with morphine did not reduce the release of TSH induced by exogenous thyrotrophin-releasing hormone (TRH) but enhanced it. This effect of morphine was also antagonized by naloxone. The above results suggested that the effect of morphine in reducing levels of serum TSH was not mediated by blocking the effect of TRH on the anterior pituitary gland, but that it was probably mediated by the inhibition of the release of TRH.     

Inactivation of thyrotrophin releasing hormone by human and rat serum.

The inactivation of thyrotrophin releasing hormone (pGlu-His-Pro-NH2, TRH) and its deamidated analogue pGlu-His-Pro-OH (TRH-OH) in human and rat serum has been studied using specific radioimmunoassays. No difference was apparent between human and rat serum with regard to proteolytic activity towards TRH and TRH-OH. It was found that the inactivation of both peptides is a saturable process. The disappearance of TRH was clearly inhibited by TRH-OH, luteinizing hormone-releasing hormone and dithiothreitol. The suppressive action of these compounds was observed to be dependent on their concentration. Proline and EDTA showed little inhibiting activity. Proline amide and pyroglutamic acid left the reaction unaffected. In no single instance could any production of TRH-OH from TRH be demonstrated.